{"nctId":"NCT00529516","briefTitle":"Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults","startDateStruct":{"date":"2007-10-15"},"conditions":["Influenza"],"count":1252,"armGroups":[{"label":"FluAS25 Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals Influenza Vaccine GSK576389A"]},{"label":"Fluarix ≥ 65 years age Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Fluarix"]},{"label":"Fluarix 18-40 years age Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Fluarix"]}],"interventions":[{"name":"Fluarix","otherNames":[]},{"name":"GSK Biologicals Influenza Vaccine GSK576389A","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study.\n* Written informed consent obtained from the subject.\n* Free of an acute aggravation of the health status as established by clinical evaluation before entering into the study.\n* If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.\n* Male or female subjects who participated in the 104888 study (NCT00377585) and were enrolled in the \\>= 65 years age group or in the 18-40 years age group .\n\nExclusion Criteria:\n\n* Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.\n* Planned administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination\n* Planned administration of an influenza vaccine other than the study vaccines during the entire study period\n* Any vaccination against influenza since January 2007\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* History of hypersensitivity to a previous dose of influenza vaccine\n* History of allergy or reactions likely to be exacerbated by any component of the vaccine(s)\n* Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests\n* Acute disease at the time of enrolment\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period\n* Any medical conditions in which IM injections are contraindicated\n* Pregnant or lactating female, or planning to become pregnant or to discontinue contraceptive precautions.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)","description":"Solicited local AEs assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"170","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Duration of Solicited Local Adverse Events","description":"Duration was expressed as the median number of days the symptom was experienced.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Solicited General Adverse Events (AEs)","description":"Solicited general AEs assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 40°C. Related: symptom assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Duration of Solicited General Adverse Events","description":"Duration was expressed as the median number of days the symptom was experienced.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any AE regardless of intensity or relationship to vaccination. Grade 3: AE that prevented normal activity. Related: AE considered by the investigator to be causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Related Medically Significant Conditions (MSCs)","description":"Medically significant conditions assessed include conditions prompting emergency room visits, hospitalizations or physician visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"137","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Hemagglutination-inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains","description":"Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"10.8","spread":null},{"groupId":"OG002","value":"48.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.5","spread":null},{"groupId":"OG001","value":"53.7","spread":null},{"groupId":"OG002","value":"143.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":null},{"groupId":"OG001","value":"79.5","spread":null},{"groupId":"OG002","value":"112.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430.6","spread":null},{"groupId":"OG001","value":"217.9","spread":null},{"groupId":"OG002","value":"251.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"82.5","spread":null},{"groupId":"OG002","value":"110.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.2","spread":null},{"groupId":"OG001","value":"152.3","spread":null},{"groupId":"OG002","value":"209.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains","description":"A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"156","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Factors for HI Antibodies Against Each of the Three Vaccine Strains","description":"Seroconversion factor was defined as the fold increase in serum HI Geometric Mean Titers post-vaccination compared to Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"5.0","spread":null},{"groupId":"OG002","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.8","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains","description":"A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to1:40 that is usually accepted as indicating protection. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"306","spread":null},{"groupId":"OG002","value":"255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"362","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"445","spread":null},{"groupId":"OG001","value":"442","spread":null},{"groupId":"OG002","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"399","spread":null},{"groupId":"OG002","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"445","spread":null},{"groupId":"OG001","value":"443","spread":null},{"groupId":"OG002","value":"268","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Cluster of Differentiation 4 (CD4) T-cells (Per Million CD4 T-cells) Producing at Least 2 Different Immune Markers","description":"Results are presented as the geometric mean number of immune response marker-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"830.72","spread":"889.90"},{"groupId":"OG001","value":"674.91","spread":"567.07"},{"groupId":"OG002","value":"1276.25","spread":"701.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2013.28","spread":"1388.55"},{"groupId":"OG001","value":"1010.22","spread":"1069.96"},{"groupId":"OG002","value":"1607.66","spread":"839.45"}]}]}]},{"type":"SECONDARY","title":"Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least CD40L and Another Immune Marker","description":"Results are presented as the geometric mean number of CD40L-positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"822.37","spread":"875.39"},{"groupId":"OG001","value":"660.01","spread":"560.95"},{"groupId":"OG002","value":"1260.65","spread":"681.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1961.18","spread":"1337.11"},{"groupId":"OG001","value":"981.82","spread":"1056.18"},{"groupId":"OG002","value":"1556.00","spread":"830.54"}]}]}]},{"type":"SECONDARY","title":"Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IFN-γ and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"513.25","spread":"586.78"},{"groupId":"OG001","value":"371.64","spread":"397.45"},{"groupId":"OG002","value":"753.45","spread":"556.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1081.11","spread":"966.36"},{"groupId":"OG001","value":"574.28","spread":"685.03"},{"groupId":"OG002","value":"870.84","spread":"589.37"}]}]}]},{"type":"SECONDARY","title":"Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least IL-2 and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"769.96","spread":"809.58"},{"groupId":"OG001","value":"634.57","spread":"518.17"},{"groupId":"OG002","value":"1030.23","spread":"585.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1644.34","spread":"1110.14"},{"groupId":"OG001","value":"856.60","spread":"855.82"},{"groupId":"OG002","value":"1288.54","spread":"664.82"}]}]}]},{"type":"SECONDARY","title":"Number of CD4 T-cells (Per Million CD4 T-cells) Producing at Least TNF-α and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD4 T-cells (per million CD4 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"586.39","spread":"698.83"},{"groupId":"OG001","value":"409.05","spread":"415.62"},{"groupId":"OG002","value":"746.02","spread":"551.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1189.34","spread":"945.05"},{"groupId":"OG001","value":"608.51","spread":"700.32"},{"groupId":"OG002","value":"921.15","spread":"549.61"}]}]}]},{"type":"SECONDARY","title":"Number of Cluster of Differentiation 8 (CD8) T-cells (Per Million CD8 T-cells) Expressing at Least 2 Different Immune Markers","description":"Results are presented as the geometric mean number of immune response marker-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":"166.35"},{"groupId":"OG001","value":"6.82","spread":"123.10"},{"groupId":"OG002","value":"3.56","spread":"247.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.75","spread":"168.54"},{"groupId":"OG001","value":"6.51","spread":"112.42"},{"groupId":"OG002","value":"3.48","spread":"79.78"}]}]}]},{"type":"SECONDARY","title":"Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least CD40L and Another Immune Marker","description":"Results are presented as the geometric mean number of CD40L-positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.19","spread":"120.88"},{"groupId":"OG001","value":"4.33","spread":"134.18"},{"groupId":"OG002","value":"2.12","spread":"220.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.09","spread":"123.89"},{"groupId":"OG001","value":"5.79","spread":"85.20"},{"groupId":"OG002","value":"3.64","spread":"71.55"}]}]}]},{"type":"SECONDARY","title":"Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IFN-γ and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.77","spread":"69.92"},{"groupId":"OG001","value":"2.64","spread":"50.62"},{"groupId":"OG002","value":"1.58","spread":"32.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":"97.36"},{"groupId":"OG001","value":"2.82","spread":"56.06"},{"groupId":"OG002","value":"2.17","spread":"28.97"}]}]}]},{"type":"SECONDARY","title":"Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least IL-2 and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.82","spread":"135.79"},{"groupId":"OG001","value":"8.43","spread":"119.70"},{"groupId":"OG002","value":"3.21","spread":"249.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.70","spread":"159.08"},{"groupId":"OG001","value":"5.64","spread":"101.15"},{"groupId":"OG002","value":"3.20","spread":"55.75"}]}]}]},{"type":"SECONDARY","title":"Number of CD8 T-cells (Per Million CD8 T-cells) Producing at Least TNF-α and Another Immune Marker","description":"Results are presented as the geometric mean number of IFN-γ -positive CD8 T-cells (per million CD8 T-cells) for pooled vaccine strains. Other immune markers assessed include Cluster of Differentiation 40 Ligand (CD40L) and interferon gamma (IFN-γ).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":"72.38"},{"groupId":"OG001","value":"2.48","spread":"42.55"},{"groupId":"OG002","value":"3.13","spread":"44.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":"89.23"},{"groupId":"OG001","value":"3.54","spread":"69.71"},{"groupId":"OG002","value":"2.73","spread":"40.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":475},"commonTop":["Pain at the injection site","Myalgia","Fatigue","Headache","Shivering"]}}}